Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05595642 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,290
- Enrollment target
- 20
- Study locations
NCT05595642: Recruiting Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Hoffmann-La Roche.
NCT05595642 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 1,290 participants, above the 615-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (110% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05595642, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,290 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Astegolimab
Study Locations (20)
Florida
- Cornerstone Research Institute - Altamonte Springs
- Invictus Clinical Research Group, LLC - Coconut Creek
- Finlay Medical Research Corporation - Greenacres City
- San Marcus Research Clinic Inc. - Miami
- Oceane7 Medical & Research Center, Inc. - Miami
- Avantis Clinical Research, LLC - Miami
- Research Institute of South Florida Inc - Miami
Alabama
- Pinnacle Research Group - Anniston
- AllerVie Clinical Research - Birmingham
- Synexus Clinical Research US, Inc. - Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
- SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS - Dothan
California
- Kern Research - Bakersfield
- VA Palo Alto Health Care System - Palo Alto
- AES - DRS - Synexus Clinical Research US, Inc. - Vista - Vista
- Allergy & Asthma Medical Group of the Bay Area - Walnut Creek
Arizona
- Pulmonary Associates PA - Glendale
- Synexus Clinical Research US, Inc. - Phoenix West - Glendale
- AES - DRS - Synexus Clinical Research US, Inc. - Tucson - Tucson
Arkansas
- Lynn Institute of The Ozarks - ERN - PPDS - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,290 participants |
| Start Date | 2022-12-29 |
| Est. Completion | 2027-09-24 |
| Phase | Phase 3 |
What NCT05595642 shows while recruiting
NCT05595642 is an interventional study that assigns participants to a tested intervention. Its 1,290 participants enrollment target places it among the larger protocols in the corpus, above the 615-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (110% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05595642 names 20 study sites across 5 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05595642 about?
NCT05595642 is a clinical study titled "A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease". This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
What is the current status of trial NCT05595642?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,290 participants. The study started on 2022-12-29. Estimated completion is 2027-09-24.
What conditions does trial NCT05595642 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT05595642?
The interventions under investigation include: Placebo (DRUG), Astegolimab (DRUG).
Who is sponsoring clinical trial NCT05595642?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05595642 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05595642's enrollment target sits among peer trials
1,290 5th of 36 higher than 32 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI